Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TENS .22/.25 1x1
TENS .20/.25 1x1 up 525%
AZTC TDA requiring call the order in for buying although i bought online earlier..lol
but there is no global warming....it's just climate change
lol....grrrrrrrr
LOL!!! i may try one of those toads myself..lol....now we know whay the toad turned into a prince when the princess licked him..lol
specs is fine now....back to normal..lol
pond is suffering from the heat same as everything else...the ph was 9.5 yesterday.....there was a frog in the pond eating a bird! blah!
our dog bit a toad and went nuts! he had a seizure and other gross stuff but is ok now.
yikes!
MAUG has always traded like that...the company doesn't dilute imo....have played this for over 2 years.
ohhhh ok...that's good....we have heat warnings here this week...index over 100
hey gold! hang on to your britches for the day real volume hits here...we will run like the wind..lol..actually, i do love the way maug moves when the buying hits.
squids n jellies? LOL! MAUG looks good today :)
oh gosh! that's rotten....you sitting on ice? ;)
ICNR INTERCONTINENTAL RESOURCES, INC.
9454 Wilshire Blvd., Suite 301
Beverly Hills, CA 90212
WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND US A PROXY
INFORMATION STATEMENT
This information statement is being furnished in connection with action taken by shareholders holding a majority of the voting power of our company. On June 12, 2007, shareholders owning 26,433,566 shares, or approximately 50.04% of the total outstanding shares on such date, approved a reverse split of the outstanding shares of common stock at the rate of one-for-five hundred (1:500). The reverse stock split will be effective twenty days following the mailing of this information statement.
There will not be a meeting of shareholders and none is required under Nevada Statutes when an action has been approved by written consent of the holders of a majority of the outstanding shares of our common stock.
This information statement is first being mailed on or about August 15, 2007, to the holders of our outstanding common stock as of June 12, 2007, the record date the shareholder written consent was signed and delivered to us. On June 12, 2007, and July 30, 2007, we had 52,820,458 shares of our common stock outstanding. Holders of the common stock are entitled to cast one vote for each share of common stock then registered in such holder’s name.
waiting for godot? lol
hmmmmm, life is good.
hope all is wonderful in your world.
ty SL :) GL today!
hey stuff! ;)
hey BIG B....sure hope so!!
dinner for two? i brought the moonshine.
AVAN .55 naz..Application for Rotarix(R) by AVANT's Partner, GlaxoSmithKline, is Accepted for Review by the FDA
Tuesday, August 14 2007 3:01 PM, EST
Business Wire "US Press Releases "
NEEDHAM, Mass.--(BUSINESS WIRE)--
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that GlaxoSmithKline's Biologics License Application (BLA) for Rotarix(R), an oral candidate vaccine for infants to prevent rotavirus gastroenteritis, has been accepted for review by the U.S. Food and Drug Administration (FDA). Severe, dehydrating gastroenteritis occurs primarily among children aged three to 35 months. Of children hospitalized with rotavirus, approximately 17 percent are younger than six months old. If approved, the GSK candidate vaccine could offer completion of the rotavirus vaccination series by four months of age. The rotavirus candidate vaccine is a live-attenuated vaccine derived from the most common human rotavirus strain. Published data show that immunity resulting from natural human rotavirus infection provides significant protection against moderate to severe disease, regardless of rotavirus strain.
The BLA for the GSK rotavirus candidate vaccine is based on one of the largest clinical development plans undertaken by a vaccine manufacturer and includes data from nearly 75,000 infants. These clinical trials were conducted in the Americas, Europe, Asia and Africa and reflect an ethnically diverse population.
"We are delighted that our partner GSK's application for Rotarix(R) has been accepted for review," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics. "The FDA review marks a significant milestone towards the global commercialization of Rotarix(R), which has already been approved for commercial use in over 90 countries worldwide, including the European Union."
About Rotarix(R)
Rotarix(R) is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by AVANT Immunotherapeutics to GSK for worldwide commercialization. The vaccine was originally developed at Cincinnati Children's Hospital Medical Center. Rotarix(R) is the first human rotavirus vaccine derived from a human virus strain available in the market. The vaccine, which is given orally, confers significant protection against rotavirus diarrhea. Clinical trials have shown high efficacy against the most prevalent rotavirus strains. It is given in a two-dose schedule beginning at six weeks of age, allowing for early protection.
About GlaxoSmithKline
GlaxoSmithKline, with U.S. operations in Philadelphia, PA, and Research Triangle Park, NC, is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world - an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children from up to six diseases in one vaccine.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and four of AVANT's products are in clinical development. AVANT's pipeline includes products for travelers' vaccines, global health, and pandemic flu needs based on AVANT's oral, rapid-protecting, single-dose and temperature stable vaccine technology.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that are subject to a variety of risks and uncertainties and reflect AVANT's current views with respect to future events and financial performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by AVANT. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT's vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other any other microbes used as bioweapons and other disease causing agents; (3) the ability to successfully complete development and commercialization of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine, VLPs and other products and AVANT's expectations regarding market growth; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other preclinical and clinical testing; (5) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other products; (6) the ability of AVANT to manage multiple late stage clinical trials for a variety of product candidates; (7) our expectations regarding our technological capabilities and expanding our focus to broader markets for vaccines; (8) our expectations regarding the cost of funding our development partnership with Select Vaccines Limited for the influenza vaccine, the opportunity to extend to other disease targets, and AVANT's ability to develop products through this collaboration; (9) changes in existing and potential relationships with corporate collaborators; (10) the availability, cost, delivery and quality of clinical and commercial grade materials supplied by contract manufacturers and partners; (11) the timing, cost and uncertainty of obtaining regulatory approvals; (12) the ability to develop and commercialize products before competitors that are superior to the alternatives developed by competitors; (13) the ability to retain certain members of management;(14) AVANT's expectations regarding research and development expenses and general and administrative expenses; (15) AVANT's expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Glaxo), revenues and expenses, including infrastructure expenses; (16) our belief regarding the validity of our patents and potential litigation; and (17) certain other factors that might cause AVANT's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors" and Management's Discussion and Analysis of Financial Condition and Results of Operations" in each of AVANT's Annual Report on Form 10-K, its Quarterly Reports on Form 8-K, as well as those described in AVANT's other press releases and filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences. These forward-looking statements were based on information, plans and estimates at the date of this press release, and we do not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.
Source: AVANT Immunotherapeutics, Inc.
AVAN .55 naz..Application for Rotarix(R) by AVANT's Partner, GlaxoSmithKline, is Accepted for Review by the FDA
Tuesday, August 14 2007 3:01 PM, EST
Business Wire "US Press Releases "
NEEDHAM, Mass.--(BUSINESS WIRE)--
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that GlaxoSmithKline's Biologics License Application (BLA) for Rotarix(R), an oral candidate vaccine for infants to prevent rotavirus gastroenteritis, has been accepted for review by the U.S. Food and Drug Administration (FDA). Severe, dehydrating gastroenteritis occurs primarily among children aged three to 35 months. Of children hospitalized with rotavirus, approximately 17 percent are younger than six months old. If approved, the GSK candidate vaccine could offer completion of the rotavirus vaccination series by four months of age. The rotavirus candidate vaccine is a live-attenuated vaccine derived from the most common human rotavirus strain. Published data show that immunity resulting from natural human rotavirus infection provides significant protection against moderate to severe disease, regardless of rotavirus strain.
The BLA for the GSK rotavirus candidate vaccine is based on one of the largest clinical development plans undertaken by a vaccine manufacturer and includes data from nearly 75,000 infants. These clinical trials were conducted in the Americas, Europe, Asia and Africa and reflect an ethnically diverse population.
"We are delighted that our partner GSK's application for Rotarix(R) has been accepted for review," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics. "The FDA review marks a significant milestone towards the global commercialization of Rotarix(R), which has already been approved for commercial use in over 90 countries worldwide, including the European Union."
About Rotarix(R)
Rotarix(R) is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by AVANT Immunotherapeutics to GSK for worldwide commercialization. The vaccine was originally developed at Cincinnati Children's Hospital Medical Center. Rotarix(R) is the first human rotavirus vaccine derived from a human virus strain available in the market. The vaccine, which is given orally, confers significant protection against rotavirus diarrhea. Clinical trials have shown high efficacy against the most prevalent rotavirus strains. It is given in a two-dose schedule beginning at six weeks of age, allowing for early protection.
About GlaxoSmithKline
GlaxoSmithKline, with U.S. operations in Philadelphia, PA, and Research Triangle Park, NC, is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world - an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children from up to six diseases in one vaccine.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and four of AVANT's products are in clinical development. AVANT's pipeline includes products for travelers' vaccines, global health, and pandemic flu needs based on AVANT's oral, rapid-protecting, single-dose and temperature stable vaccine technology.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that are subject to a variety of risks and uncertainties and reflect AVANT's current views with respect to future events and financial performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by AVANT. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT's vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other any other microbes used as bioweapons and other disease causing agents; (3) the ability to successfully complete development and commercialization of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine, VLPs and other products and AVANT's expectations regarding market growth; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other preclinical and clinical testing; (5) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies of TP10, CETi-1, CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other products; (6) the ability of AVANT to manage multiple late stage clinical trials for a variety of product candidates; (7) our expectations regarding our technological capabilities and expanding our focus to broader markets for vaccines; (8) our expectations regarding the cost of funding our development partnership with Select Vaccines Limited for the influenza vaccine, the opportunity to extend to other disease targets, and AVANT's ability to develop products through this collaboration; (9) changes in existing and potential relationships with corporate collaborators; (10) the availability, cost, delivery and quality of clinical and commercial grade materials supplied by contract manufacturers and partners; (11) the timing, cost and uncertainty of obtaining regulatory approvals; (12) the ability to develop and commercialize products before competitors that are superior to the alternatives developed by competitors; (13) the ability to retain certain members of management;(14) AVANT's expectations regarding research and development expenses and general and administrative expenses; (15) AVANT's expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Glaxo), revenues and expenses, including infrastructure expenses; (16) our belief regarding the validity of our patents and potential litigation; and (17) certain other factors that might cause AVANT's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors" and Management's Discussion and Analysis of Financial Condition and Results of Operations" in each of AVANT's Annual Report on Form 10-K, its Quarterly Reports on Form 8-K, as well as those described in AVANT's other press releases and filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences. These forward-looking statements were based on information, plans and estimates at the date of this press release, and we do not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.
Source: AVANT Immunotherapeutics, Inc.
Signature Stock Transfer, Inc.
2301 Ohio Drive - Suite 100
Plano, Texas 75093
Telephone Number 972 612 4120
Facsimile Number 972 612 4122
Email Address signaturestocktransfer@msn.com
yep
8/15/2007 PEDG 1-600 R/S ** PrimEdge, Inc. NEW Common Stock PEDI PrimEdge, Inc. Common Stock
8/13/2007 SMEG 1-40 R/S ** StarMed Group, Inc. Common Stock SMED StarMed Group, Inc. NEW Common Stock
8/13/2007 SLXI 1-35,000 R/S ** Satelinx International, Inc. Common Stock AFFN Affinity Networks, Inc. Common Stock
8/13/2007 EGTA 1-100 R/S ** 8888 Acquisition Corporation Common Stock EGHA 8888 Acquisition Corporation New Common Stock
8/13/2007 BNSIA BNS Holding, Inc. Class A Common Stock BNSSA BNS Holding, Inc. Class A NEW Common Stock 1-200 R/S immediately followed 200-1 F/S. Payable upon surrender. Shareholders holding less than 200 shares will be cashed out at a rate of $13.62/sh. **
8/13/2007 ACHI 1-7 R/S ** AmeriChip International Inc. Common Stock ACII AmeriChip International Inc. NEW Common Stock
8/10/2007 SKYI 1-100 R/S Skynet Telematics, Inc. Common Stock BSMP Brisam Corporation Common Stock ; Any shareholder with less than 100 shs presplit will be reduced to 10 shs. **
8/10/2007 RCAU 1-40 R/S ** Rocket City Automotive Group, Inc. Common Stock RCTY Rocket City Enterprises, Inc. Common Stock
8/10/2007 BPWW 1-250 R/S ** Big Apple Worldwide, Inc. Common Stock BPWI Big Apple Worldwide, Inc. New Common Stock
ROTFL!!! perfect ;) and of course it goes without saying what bull would have..lol
no, MRDALE...this is simply a record of the Reverse Splits of the company....the new company will look good if it conitnues to show no new RSs....it has already been 1½ years since the last RS which is a new record for WNSH.
best of luck,
sub
TOSD! go get your diaper changed ..you're full of shit
TDA = order cannot be placed
you didn't miss anything..lol
ok, i'm gone for the rest of the day...GL!!! :)
LNGT .014...Laser Energetics, Inc. Completes Laser Study Funded by Fortune 100 Defense Company
PRINCETON, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Laser Energetics, Inc. (Pink Sheets: LNGT) is pleased to announce the Company has completed a study on its BrightStar(TM) Alexandrite laser, funded by a Fortune 100 Defense company for $25,000. LEI contributed information for the study, about LEI's Alexandrite laser technology. The study compared 18 different lasers for a 'remote sensing' laser application which will be for military use. The Company provided a report on Alexandrite lasers in which it defined the technical advantages of this tunable laser technology over other lasers.
This laser technology could be used on the battlefield for detection of chemical and biological warfare agents, as well as detection of high explosives for homeland security applications. The Company's technology was deemed one of the top three choices for this remote sensing laser application out of 18 presented from various other laser companies.
'We believe that Laser Energetics is on the fast track with the laser study and development of the BrightStar(TM) Alexandrite laser. We will continue to develop and test this product within multiple market sectors outside of the military and further Company growth,' stated Robert Battis, CEO of Laser Energetics, Inc.
Laser Energetics recently announced Patent filings (PCT/US06//015339) with the US Patent office encompassing a new type of Alexandrite laser; the Company has named the new technology the BrightStar(TM) Alexandrite laser. This Alexandrite laser incorporates a DP Nd:YAG laser pump as its excitation source, to create tunable Alexandrite laser light that is deliverable in IR, UV or Deep UV wavelengths efficiently and reliably.
About Laser Energetics, Inc.:
LEI has and continues to develop a comprehensive and strategic laser product line that addresses applications in Industry, Science, Medicine and the Military. The Company has had a primary focus on its Alexandrite laser technology. These tunable solid state lasers are unique in that they can be conductively air cooled to compete favorably against water cooled lasers in many applications. In addition, they have one of the greatest wavelength ranges with tune-ability ranging a bandwidth of up to 275nm. The Company is pursuing markets that are diverse yet can use the same laser with their compact user friendly design. This laser technology provides a sustainable advantage over many other lasers because of their tune-ability, conductively air cooled operation, and their efficiency allowing these lasers to operate at 110 Volts as compared to other less efficient competitive lasers that are large and need 220 Volts to operate.
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are 'forward-looking statements' within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
To automatically receive instant updates, press releases, and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
SOURCE Laser Energetics, Inc.
Source: PR Newswire (August 7, 2007 - 7:31 AM EST)
News by QuoteMedia
www.quotemedia.com